| DC21426 |
NSC654259 |
A novel small molecule Wnt signaling inhibitor that targets the cysteine-rich domain of Frizzled, specifically binds to the Wnt binding site on the Frizzled8 cysteine-rich domain with Kd of 2.9 uM, IC50 of 5.7 uM.. |
|
| DC11877 |
F3406 |
A novel small-molecule arenaviruse inhibitor that exhibits strong anti-LCMV activity (IC50<1 uM) without cell toxicity. |
|
| DC11908 |
Ralaniten |
A novel small-molecule inhibitor of androgen receptor (AR) N-terminal domain inhibitor for the treatment of advanced prostate cancer. |
|
| DC11909 |
Ralaniten acetate |
A novel small-molecule inhibitor of androgen receptor (AR) N-terminal domain inhibitor for the treatment of advanced prostate cancer. |
|
| DC20873 |
CCT-031374 hydrobromide |
A novel small-molecule Wnt signaling inhibitor that inhibits TCF-dependent transcription with IC50 of 6.1 uM in 7dF3 reporter assay. |
|
| DC21232 |
Licogliflozin |
A novel sodium glucose transporter type 1 and type 2 (SGLT1/2) inhibitor for the oral treatment of type 2 diabetes.. |
|
| DC23587 |
AMG1 |
A novel specific CRAC channel inhibitor that blocks function of effector but not regulatory T cells in vitro and attenuates the pogression and severity of EAE in vivo. |
|
| DC21056 |
GMI-1271
Featured
|
A novel specific glycomimetic E-Selectin antagonist with Kd of 0.46 uM, IC50 of 1.75 uM. |
|
| DC11795 |
BL-140 |
A novel specific p110β inhibitor with IC50 of 5.74 nM. |
|
| DC22863 |
FPND |
A novel specific ROCK1 kinase inhibitor with IC50 of 11.2 uM, without inhibitory activity against ROCK2. |
|
| DC20372 |
Elismetrep |
A novel specific TRPM8 channel antagonist for treatment or prevention vasomotor symptoms.. |
|
| DC12000 |
AUT2 |
A novel specific, cell permeant modulator of Kv3 channels with EC50 of 0.9 and 1.9 uM for Kv3.1b and Kv3.2a, respectively. |
|
| DC5893 |
SCD1 inhibitor
Featured
|
A novel stearoyl-CoA desaturase1 (SCD1) inhibitor.The compound exhibited robust in vivo activity with dose-dependent desaturation index lowering effects. |
|
| DC22931 |
1Z105 |
A novel synthetic, orally bioavailable TLR4/MD2 ligand, significantly reduces the IL-6 secretion by subsequent challenge with LPS at 0.63 uM. |
|
| DC23945 |
Pyr10
Featured
|
Pyr10 is a pyrazole derivative and a selective TRP cation 3 (TRPC3) inhibitor. Pyr10 inhibits Ca2+ influx in carbachol-stimulated TRPC3-transfected HEK293 cells with an IC50 of 0.72 μM (IC50 of 13.08 μM for store operated Ca2+ entry in BRL-2H3 cells). Pyr10 has the ability to distinguish between receptor-operated TRPC3 and native stromal interaction molecule 1 (STIM1)/Orai1 channels[1]. |
|
| DC11694 |
STK899704 |
A novel tubulin inhibitor that inhibits the proliferation of cancer cell lines with IC50 of 0.2-1.0 uM. |
|
| DC21298 |
Uprifosbuvir |
A novel uridine nucleotide analog HCV NS5B polymerase inhibitor for treatment of HCV infection combined with Grazoprevir and Ruzasvir.. |
|
| DC10646 |
VPS34 inhibitor(Compound 80)
Featured
|
A novel VPS34 inhibitor. |
|
| DC11825 |
MK-8876 |
A novel, broadly acting non-nucleoside inhibitor of HCV NS5B polymerase with IC50 of 3 nM and 2 nM for GT1b and GT2a, respectively. |
|
| DC22790 |
MELK-T1 hydrochloride |
A novel, cell-permeable, potent and selective inhibitor of MELK kinase domain with IC50 of 37 nM. |
|
| DC23430 |
THRX-200495 |
A novel, dual-acting muscarinic receptor antagonist and β2-adrenoceptor agonist (MABA) with pKi of 9.21/9.53 for hM2/M3, pKi of 9.37 for β2-adrenoceptor. |
|
| DC23454 |
V0162 |
A novel, high affinity and long-acting antagonist of human M3 muscarinic acetylcholine receptor with pKi of 9.03-9.21. |
|
| DC22756 |
CHF6001 |
A novel, highly potent and selective phosphodiesterase 4 (PDE4) inhibitor with IC50 of 0.026 nM. |
|
| DC24013 |
MUT-056399 |
A novel, highly potent inhibitor of the FabI enzyme of both Staphylococcus aureus and Escherichia coli. |
|
| DC11676 |
NS15370
Featured
|
A novel, highly potent positive modulator of Kv7 channels with EC50 of 100 nM (Kv7.2-Kv7.5). |
|
| DC21389 |
NKTR-181 |
A novel, long-acting and orally active, selective mu-opioid agonist that displays higher binding affinity (Ki=237 nM) at the MOR than kappa and delta opioid receptors (>100-fold). |
|
| DC12011 |
KU-32 |
A novel, novobiocin-based, C-terminal inhibitor of Hsp90 and a potent inducer of Hsp70. |
|
| DC24094 |
Dofequidar |
A novel, orally active quinoline compound that can reverse P-glycoprotein (P-gp)-mediated MDR. |
|
| DC22599 |
GLPG-0492 |
A novel, orally active, non-steroidal selective androgen receptor modulator (SARM) with in vitro potency of 13 nM. |
|
| DC21542 |
PTC-596 |
A novel, orally active, small molecule inhibitor of BMI-1 that accelerates BMI-1 degradation, inhibits AML cells growth with IC50 of <100 nM. |
|
